首页> 外国专利> T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS

T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME AGAINST PRAME POSITIVE CANCERS

机译:T细胞受体和免疫疗法使用相同的抗正离子癌症

摘要

The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
机译:本发明涉及针对肿瘤相关抗原(TAA),特别是针对黑色素瘤的优先表达抗原(PRAME)的抗原识别构建体。本发明特别提供了对本发明的肿瘤表达抗原具有选择性和特异性的新型基于T细胞受体(TCR)的分子。本发明的TCR及其衍生的TAA结合片段可用于诊断,治疗和预防表达TAA的癌性疾病。还提供了编码本发明的抗原识别构建体的核酸,包含这些核酸的载体,表达抗原识别构建体的重组细胞以及包含本发明的化合物的药物组合物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号